These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 7117789)

  • 1. 5-aminosalicylic acid in a slow-release preparation: bioavailability, plasma level, and excretion in humans.
    Rasmussen SN; Bondesen S; Hvidberg EF; Hansen SH; Binder V; Halskov S; Flachs H
    Gastroenterology; 1982 Nov; 83(5):1062-70. PubMed ID: 7117789
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A new slow-release form of 5-aminosalicylic acid for the oral treatment of inflammatory bowel disease. Biopharmaceutic and clinical pharmacokinetic characteristics.
    Klotz U; Maier KE; Fischer C; Bauer KH
    Arzneimittelforschung; 1985; 35(3):636-9. PubMed ID: 4039590
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 5-Aminosalicylic acid containing drugs. Delivery, fate, and possible clinical implications in man.
    Christensen LA
    Dan Med Bull; 2000 Feb; 47(1):20-41. PubMed ID: 10709142
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative pharmacokinetics of equimolar doses of 5-aminosalicylate administered as oral mesalamine (Asacol) and balsalazide: a randomized, single-dose, crossover study in healthy volunteers.
    Sandborn WJ; Hanauer SB; Buch A
    Aliment Pharmacol Ther; 2004 May; 19(10):1089-98. PubMed ID: 15142198
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systemic uptake of 5-aminosalicylic acid from olsalazine and eudragit L coated mesalazine in patients with ulcerative colitis in remission.
    Ewe K; Becker K; Ueberschaer B
    Z Gastroenterol; 1996 Apr; 34(4):225-9. PubMed ID: 8686349
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 5-Aminosalicylic acid for the treatment of inflammatory bowel disease.
    Dew MJ; Evans BK; Rhodes J
    Gastroenterology; 1984 Aug; 87(2):480-1. PubMed ID: 6735091
    [No Abstract]   [Full Text] [Related]  

  • 7. The optimal dose of 5-aminosalicylic acid in active ulcerative colitis: a dose-finding study with newly developed mesalamine.
    Kruis W; Bar-Meir S; Feher J; Mickisch O; Mlitz H; Faszczyk M; Chowers Y; Lengyele G; Kovacs A; Lakatos L; Stolte M; Vieth M; Greinwald R
    Clin Gastroenterol Hepatol; 2003 Jan; 1(1):36-43. PubMed ID: 15017515
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chemistry, pharmacology, pharmacokinetics, and clinical applications of mesalamine for the treatment of inflammatory bowel disease.
    Small RE; Schraa CC
    Pharmacotherapy; 1994; 14(4):385-98. PubMed ID: 7937276
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Exacerbation of ulcerative colitis and Crohn's disease following a change-over from salazosulfapyridine to 5-aminosalicylic acid].
    Feurle GE; Helmstädter V
    Dtsch Med Wochenschr; 1986 May; 111(18):721-2. PubMed ID: 2870908
    [No Abstract]   [Full Text] [Related]  

  • 10. Absorption and excretion of a single 1-g dose of azodisal sodium in subjects with ileostomy.
    Sandberg-Gertzén H; Ryde M; Järnerot G
    Scand J Gastroenterol; 1983 Jan; 18(1):107-11. PubMed ID: 6675167
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sulfasalazine and new analogues.
    Friedman G
    Am J Gastroenterol; 1986 Feb; 81(2):141-4. PubMed ID: 2868653
    [No Abstract]   [Full Text] [Related]  

  • 12. 5-Aminosalicylic acid enemas in patients with active ulcerative colitis. Influence of acidity on the kinetic pattern.
    Bondesen S; Nielsen OH; Jacobsen O; Rasmussen SN; Hansen SH; Halskov S; Binder V; Hvidberg EF
    Scand J Gastroenterol; 1984 Jul; 19(5):677-82. PubMed ID: 6382570
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of a slow-release 5'-aminosalicylic acid preparation on disease activity in Crohn's disease.
    Saverymuttu SH; Gupta S; Keshavarzian A; Donovan B; Hodgson HJ
    Digestion; 1986; 33(2):89-91. PubMed ID: 3512352
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Steady state disposition of 5-aminosalicyclic acid following oral dosing.
    Klotz U; Stracciari GL
    Arzneimittelforschung; 1993 Dec; 43(12):1357-9. PubMed ID: 8141827
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Current therapeutic possibilities in chronic inflammatory intestinal diseases].
    Schölmerich J
    Praxis (Bern 1994); 1995 Jan; 84(2):29-33. PubMed ID: 7839043
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [New developments in therapy with 5-aminosalicylic acid preparations in ulcerative colitis and Crohn disease].
    Kruis W
    Z Gastroenterol Verh; 1991 Mar; 26():154-6. PubMed ID: 1714132
    [No Abstract]   [Full Text] [Related]  

  • 17. Pharmacokinetics of a 5-aminosalicylic acid enteric-coated tablet in patients with Crohn's disease or ulcerative colitis and in healthy volunteers.
    Norlander B; Gotthard R; Ström M
    Aliment Pharmacol Ther; 1990 Oct; 4(5):497-505. PubMed ID: 2129637
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Colonic azodisalicylate metabolism determined by in vivo dialysis in healthy volunteers and patients with ulcerative colitis.
    Lauritsen K; Hansen J; Ryde M; Rask-Madsen J
    Gastroenterology; 1984 Jun; 86(6):1496-500. PubMed ID: 6143704
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Delayed-release mesalazine (5-aminosalicylic acid): coat dissolution and excretion in ileostomy subjects.
    Riley SA; Tavares IA; Bennett A; Mani V
    Br J Clin Pharmacol; 1988 Aug; 26(2):173-7. PubMed ID: 3207553
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Topical and systemic availability of 5-aminosalicylate: comparisons of three controlled release preparations in man.
    Christensen LA; Fallingborg J; Abildgaard K; Jacobsen BA; Sanchez G; Hansen SH; Bondesen S; Hvidberg EF; Rasmussen SN
    Aliment Pharmacol Ther; 1990 Oct; 4(5):523-33. PubMed ID: 2129640
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.